Apricus Biosciences, Inc. (NASDAQ: APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. The company has initiated a phase IIb trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions in the future. Apricus’s lead commercial product, Vitaros®, is currently approved in Europe and Canada for the treatment of erectile dysfunction and is being commercialized in several European markets. For more information, visit the company’s website at www.apricusbio.com.